Similar Articles |
|
Salon.com March 12, 2002 Janelle Brown |
Saying no to propaganda Critics say the government's new anti-drug campaign is reactionary and moralistic. Worse, it may not even work... |
The Motley Fool February 28, 2011 Brian Orelli |
Rare Diseases, Big Opportunity "Orphan" drugs to keep your eye on. |
Chemistry World November 2010 |
Column: In the Pipeline Should drug companies focus on big markets and the blockbuster dream? |
Salon.com June 30, 2001 Daniel Forbes |
The quiet death of prime-time propaganda With no fanfare, the White House drug office pulls the plug on its controversial program to pay TV networks for putting anti-drug messages in popular shows... |
The Motley Fool July 12, 2010 Ryan McBride |
Synta Pharma CEO Trumpets New Top Cancer Drug Synta Pharmaceuticals has been climbing back from one of the Boston area's highest-profile clinical trial failures of 2009. |
Reason August 2003 Julian Sanchez |
Bad Ad The Office of National Drug Control Policy once occupied itself with protecting Americans from the total ruin that follows inexorably from that first puff on a joint. Its new mission is apparently to protect us (and, coincidentally, its budget) from Americans who question its policy. |
The Motley Fool February 16, 2010 Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
BusinessWeek March 7, 2005 Amy Barrett |
Will Drugmakers Back Off The Hard Sell? Drug ads need to return to more balanced communication of risks and benefits and not depend so much on catchy phrases and images. The question is whether the industry is ready to take that lesson to heart. |
The Motley Fool July 30, 2010 Brian Orelli |
A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs. |
Chemistry World March 2011 |
Column: In the pipeline Drug discovery is an inherently risky business. Derek Lowe tries to balance some of the risk equations |
The Motley Fool May 21, 2010 Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. |
Reason April 2004 Jacob Sullum |
Data: Lack of PRIDE Is the government winning the war on drugs? |
Pharmaceutical Executive January 1, 2011 Eric Boothe |
The Right Mix for 2011 Incorporating the proper blend of media into your marketing initiatives will help to increase the flexibility and success of your pharma marketing campaigns. |
Chemistry World July 16, 2010 Matt Wilkinson |
Bittersweet victory for GSK's Avandia GlaxoSmithKline has received a muted 'thumbs up' from a US regulatory advisory panel for its much-maligned Type 2 diabetes drug Avandia (rosiglitazone), making it likely the US Food and Drug Administration will allow the UK-based pharma giant to continue selling the drug in the US. |
Salon.com July 27, 2000 Daniel Forbes |
Fighting "Cheech & Chong" medicine Did the White House drug office go too far in trying to stop the spread of medical marijuana initiatives? |
CRM October 2013 Marshall Lager |
What's Your Marketing Plan? Good marketing campaigns have a set goal. There's a reason why. |
Salon.com June 23, 2000 Daryl Lindsey |
Drug cookies Why was the White House drug office monitoring your computer behavior? |
The Motley Fool January 28, 2010 Brian Orelli |
How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward. |
Entrepreneur November 2004 Kim T. Gordon |
Sock It to 'Em Can a negative marketing campaign have positive results? Here's what to know before you strike the first blow. |
The Motley Fool March 4, 2010 Brian Orelli |
A Painless Drug Deal Bristol-Myers licenses pain drug from Allergan. |
Reason January 2004 Renee Moilanen |
Just Say No Again The old failures of new and improved anti-drug education |
HBS Working Knowledge May 21, 2008 John Quelch |
Going Negative in Political Advertising Negative ads ask us to vote against someone rather than for someone, an approach that sometimes works in political advertising. |
BusinessWeek August 15, 2005 Barrett & Weintraub |
Drugmakers Are Changing Channels All those "Ask your doctor if it's right for you" ads on TV haven't delivered. As drugmakers labor to develop more educational and balanced pitches, they're also trying to better target their messages. |
The Motley Fool March 31, 2011 Brian Orelli |
Drug Warning Labels: The Good, Bad, and Ugly Once a drug is approved, investors can't fall asleep and ignore FDA announcements about drugs. They come in different varieties, but warnings tend to be of the bad and ugly variety more often than the good. |
The Motley Fool January 29, 2010 Brian Orelli |
How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years. |
Entrepreneur November 2003 Kim T. Gordon |
Total Recall Find out what the latest research can teach you about creating ads your prospects won't forget. |
InternetNews September 11, 2009 |
Microsoft Takes to the Airwaves for Windows 7 First ads debut for the upcoming operating system. |
Search Engine Watch January 14, 2004 Christine Churchill |
Day of Reckoning in Search Engine Advertising Overture's announcement that it plans to separate contextual advertising from regular keyword-based search results and ads has garnered kudos from the search engine marketing community. Will Google follow suit? |